Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Clin Chim Acta ; 239(1): 91-101, 1995 Jul 31.
Artículo en Inglés | MEDLINE | ID: mdl-7586591

RESUMEN

Plasma levels of human leukocyte elastase, a serine proteinase stored in the azurophilic granules of polymorphonuclear granulocytes, increase in the early stages of several inflammatory diseases. We studied the intracellular enzyme activity by cytochemical quantitative image analysis and the amount of elastase released in plasma by an automatic immunoactivation immunoassay method in 66 patients with inflammatory diseases and in a control group. The patients were divided into two groups with infective disease (severe and moderate) and one group with non-infective inflammation. Intracellular activity and plasmatic levels of elastase were also compared with other inflammatory markers, i.e. erythrocyte sedimentation rate, C-reactive protein, alpha 1-antitrypsin, haptoglobin, alpha 1-acid glycoprotein and fibrinogen. Our studies suggest that plasma and leukocyte elastase are correlated both with etiology and with the severity of the inflammation.


Asunto(s)
Proteínas de Fase Aguda/metabolismo , Inflamación/sangre , Elastasa Pancreática/análisis , Elastasa Pancreática/sangre , Adulto , Anciano , Anciano de 80 o más Años , Sedimentación Sanguínea , Diagnóstico Diferencial , Fibrinógeno/metabolismo , Histocitoquímica , Humanos , Infecciones/sangre , Infecciones/diagnóstico , Elastasa de Leucocito , Persona de Mediana Edad , Curva ROC
2.
Minerva Med ; 81(11): 831-4, 1990 Nov.
Artículo en Italiano | MEDLINE | ID: mdl-2255420

RESUMEN

A case of pleuropulmonary manifestation as the first symptom of rheumatoid arthritis is reported; articular involvement followed at a later stage. Pleuropulmonary localisation of rheumatoid arthritis is varied and infrequent; it is seldom the first manifestation of illness. This case was particular because isolated pleuropulmonary symptom appeared in a subject negative rheumatoid factor. The patient improved after initial NSAIDS treatment, followed by corticosteroids and NSAIDS together, leading to the resolution of clinical and x-ray symptoms.


Asunto(s)
Artritis Reumatoide/complicaciones , Enfermedades Pulmonares/etiología , Enfermedades Pleurales/etiología , Femenino , Humanos , Persona de Mediana Edad
3.
Recenti Prog Med ; 90(11): 579-84, 1999 Nov.
Artículo en Italiano | MEDLINE | ID: mdl-10608146

RESUMEN

This study was designed to assess the analytical sensitivity and rate of agreement between commercial methods and reagents, among the most used in Italy for the detection of autoantibodies to extractable nuclear antigens (ENA). Sixty-eight serum samples from patients with clinically diagnosed systemic rheumatic diseases were aliquoted and distributed to 4 hospital laboratories; three ELISA (Elias, Shield, Inova) and 1 immunoblot method (Euroimmun) were used. Overall agreement between the test reagents, for each anti-ENA specificity, was 69.1% for Ro/SSA, 83.3% for La/SSB, 70.6% for RNP, 73.5% for Sm, 91.1% for Jo1, and 82.3% for Scl70. Lack of specificity (i.e., false positive reactions) was the most important cause of low concordance. When the data were analysed according to the clinical diagnosis, total agreement and specificity improved. However, a significant difference in terms of sensitivity was observed in the SLE group (30 sera) for RNP (positivity ranged from 20% to 43%) and for Sm (from 7% to 37%), and in the Sjögren's syndrome group (13 sera) for anti-La/SSB (from 8% to 38%). Comparable data were obtained for anti-Ro/SSA (from 70% to 77%) both in the SLE and the Sjögren's syndrome group. Sensitivity of all 4 reagents was good in detecting anti-Scl70 autoantibodies in the 8 patients with diffuse systemic sclerosis, as well as anti-Jo1 autoantibody in the 5 polymyositis patients, with a 100% and a 95% agreement, respectively. These data suggest the need of a better standardization of commercial reagents and analytical procedures, and the opportunity that every laboratory should perform anti-ENA determination by at least two different methods, since none of the methods tested was completely reliable in detecting all anti-ENA autoantibody specificities.


Asunto(s)
Anticuerpos Antinucleares/análisis , Autoantígenos/inmunología , Enfermedades Autoinmunes/diagnóstico , Enfermedades del Tejido Conjuntivo/diagnóstico , Ensayo de Inmunoadsorción Enzimática/métodos , Immunoblotting , Enfermedades Autoinmunes/inmunología , Enfermedades del Tejido Conjuntivo/inmunología , Humanos , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/inmunología , Juego de Reactivos para Diagnóstico , Sensibilidad y Especificidad , Síndrome de Sjögren/diagnóstico , Síndrome de Sjögren/inmunología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda